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INTRODUCTION:  Intraductal  papillary  mucinous  neoplasm  is  an  increasingly  recognized  disease  with  vary-
ing  premalignant  potential  and  unclear  incidence,  characterized  by  a mucin-producing  epithelium  and
dilation  of the  pancreatic  duct.
PRESENTATION OF  CASE:  We  present  the  ﬁrst documented  case  of  distant  intestinal  intraductal  papillary
mucinous  neoplasm  recurrence  following  total  pancreatectomy  for side-branch  non-invasive  borderline
malignant  intraductal  papillary  mucinous  neoplasm.
DISCUSSION: We  review  the  current  literature  in  order  to try  and answer  important  questions  regarding
our  ability  to predict  intraductal  papillary  mucinous  neoplasm  recurrence,  our  understanding  of  theecurrence
anagement
PMN
potential  for  recurrence  and what  follow-up  should  be recommended  to  properly  monitor  recurrence
after  a benign,  albeit  borderline  malignant,  side-branch  lesion  resection.
CONCLUSION: Our case  report  conﬁrms  that  the  low  risk  classiﬁcation  of  an  intraductal  papillary  mucinous
neoplasm  lesion  even  after  total  pancreatectomy  does  not  always  predict  recurrence  and that  deﬁnitive
prognostic  factors  of recurrence  in the setting  of  non-invasive  disease  have  yet to  be identiﬁed.  A  vigilant
long-term  approach  to follow-up  may  thus  be  required  even  in  low  risk  cases
gical © 2013 Sur
. Introduction
Intraductal papillary mucinous neoplasm (IPMN) is a rare
isease of increasing but unclear incidence.1–3 It occurs more fre-
uently in men  in their sixth to seventh decade1 and patients most
ommonly present with abdominal pain, acute pancreatitis, weight
oss, new onset of diabetes, jaundice and exocrine insufﬁciency.1
he lesion is characterized by mucin-producing epithelium dis-
laying a papillary architecture and is associated with dilation of
he pancreatic ducts. It can be classiﬁed anatomically as main-
ranch, side-branch or mixed depending on the location of the
ain lesion and the dilation of the pancreatic ducts on imaging.
t may  also histologically be invasive or non-invasive. Depending
n anatomical, histopathological classiﬁcation, and patient factors,
n IPMN can be managed with observation or surgical resection.1
he 5-year survival rate of cases selected for operation ranges
rom 36 to 77% depending on the original presence of a primary
r metastatic malignancy.4 Recurrence is seen in 7–43% of cases
epending on the histopathological characteristics of the lesion.1
Abbreviations: IPMN, intraductal papillary mucinous neoplasm; MRCP, magnetic
esonance  cholangiopancreatography; EUS, endoscopic ultrasound.
∗ Corresponding author. Tel.: +1 514 804 0629.
E-mail addresses: nayima.c@gmail.com (N.M.C. Dejean),
inziana.dumitra@mail.mcgill.ca (S. Dumitra), jeffrey.barkun@muhc.mcgill.ca
J.S.  Barkun).
210-2612 ©  2013 Surgical Associates Ltd. Published by Elsevier Ltd.        
ttp://dx.doi.org/10.1016/j.ijscr.2013.05.009
Open access under CC BY-Associates Ltd. Published by Elsevier Ltd.   
When the anatomical classiﬁcation of a lesion points toward a
low malignant potential, for example with an asymptomatic side-
branch cystic lesion without mural nodule or main branch dilation,
it is possible to manage IPMN conservatively, with yearly imaging.5
However, the potential for malignancy associated with main duct
IPMN usually warrants its removal.
2. Case report
We  present the case of a 76-year-old man  diagnosed with IPMN
in May  2004. A CT scan at the time showed a 10 cm multicystic
mass extending to the pancreas head and body with duct dilatation
up to the tail. The presence of a mucinous tumor of the pan-
creas, possibly a side-branch IPMN, was  subsequently conﬁrmed
by a magnetic resonance cholangiopancreatography (MRCP) and
endoscopic ultrasound (EUS). The patient’s CA19-9 level was  not
available at the time. Pre-operative biopsies were unsuccessful,
but malignancy was suspected. In July 2004, at laparotomy, most
of the pancreas and the posterior wall of the stomach formed a
large mass and so the patient underwent a total pancreatectomy,
cholecystectomy, gastric antrectomy and splenectomy with a hep-
aticojejunostomy and gastrojejunostomy. Intra-operative frozen
sections showed dysplastic mucosa of the main cyst wall, and could
Open access under CC BY-NC-ND license. not rule out cancer. The ﬁnal pathology showed a non-invasive,
well-differentiated IPMN with clear margins and ten resected
lymph nodes free of tumor. The specimen was  described as “bor-
derline malignant” due to its size (10.5 cm at its largest diameter)
NC-ND license. 
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nd exhibited pancreatic intraepithelial neoplasia (PanIN) grades I
o  III.
The patient was then followed with yearly serum CA19-9 levels,
s well as yearly thoracoabdominal imaging. He remained asymp-
omatic. On CT imaging in 2010, suspicious tissue nodularities were
oted in the hilum of liver. A PET-CT revealed a hypermetabolic
ocus (SUV of 8.6) at the site of the surgical clips in the region
f the choledochojejunostomy. The patient then underwent bal-
oon enteroscopy of the afferent hepaticojejunal limb that revealed
 large small bowel polypoid mass near the hepaticojejunostomy
ith no signs of common bile duct obstruction. Biopsies were found
o be consistent with recurrent IPMN. An abdominal MRI  con-
rmed the presence of a 12 mm × 16 mm intra-luminal lesion at
he suspected location with no extension beyond the bowel wall.
o other changes or suspicious lesions were found. Over the next
onths the original and the newer pathological slides were exten-
ively reviewed, as the patient was reticent to undergo operation.
n January 2011 a whole body PET scan demonstrated a decrease
n the metabolic activity of the mass (SUV of 5.7 from 8.6) and no
ew lesions. An MRCP showed interval enlargement of the lesion
23 mm × 16 mm)  with no evidence of biliary obstruction. Given
he interval enlargement of the lesion, the patient agreed to oper-
tion and underwent a small bowel resection with revision of the
epaticojejunostomy to the level of the hepatic duct bifurcation.
athology revealed a recurrence of non-invasive IPMN and the mar-
ins of resection were once again negative. Following an uneventful
peration, the patient remains symptom-free.
. Discussion
This is the ﬁrst description of an extra-pancreatic recurrence
f a side-branch non-invasive IPMN following total pancreatec-
omy. Masaya et al. previously reported in a 74 years old man  a
ecurrence of a non-invasive IPMN in the stomach after partial
ancreatectomy.6 The pattern of spread of IPMN was  attributed
o the presence of a ﬁstula from the remnant pancreas. However
n the present case, there was no pancreaticoenteric anastomosis,
nd no pancreas gland remained, making the source of recurrence
 mystery. Enteric spread at the time of the original surgery and
low subsequent growth remains a hypothetical possibility.
Our  case report raises an important question regarding our
bility to predict IPMN recurrence based on histopathologic and
natomical classiﬁcation. It also raises questions regarding our
nderstanding of the potential for recurrence of IMPN and what
ollow-up should be recommended to properly monitor recur-
ence after a benign, albeit borderline malignant, side-branch lesion
esection.
IPMN lesions are classiﬁed based on their morphological and
istologic features. MRCP or EUS are initially used in order to
emonstrate the side branch communication needed to make the
iagnosis. CT can be used thereafter as a primary modality for pre-
perative characterization.4,7,8 The prediction of the IPMN variant
an be limited when using a CT scan8 and the use of adjunct imaging
odalities such as MRI, MRCP and ERCP can help better character-
ze the lesion.4,8 A dilated main pancreatic duct with a diameter
f 10 mm points toward a main duct IPMN.5,7–9 On the other hand
hen the main duct is of normal size and a side-branch communi-
ation is visualized, a branch duct IPMN variant is suspected.4,7,9
t is however possible for a branch-duct lesion to be multifocal
nd involve the entire pancreas,5,10 as in the current case. This
ype of lesion needs to be carefully differentiated from the mixed
PMN variant in which there is a combination of imaging features
rom both main and branch duct IPMN.7 The latter is considered
o be a variant of main duct IPMN and thus known to have a
reater potential for malignancy associated with the main ductPEN  ACCESS
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lesion.  Histologically, lesions are graded as low/benign, intermedi-
ate/borderline, or high-grade dysplasia/carcinoma with or without
presence of invasiveness. Once invasiveness is conﬁrmed, the histo-
logical IPMN subtype identiﬁes a distinct probability of progression
to pancreatic cancer with the pancreatobiliary, intestinal, gastric
foveolar and oncocytic subtypes having the highest malignant
potential and the tubular subtype the least.
The main duct IPMN variant is three times more likely to be
invasive than the branch type8 and is associated with cancer in
60–83%.11 Current recommendation is therefore to resect all main
duct and mixed IPMN variants.5 The guidelines for branch duct
IPMN allow for a more conservative approach since this lesion
seems to be associated with a malignancy rate of 6–46%.5 Therefore
observation is possible in many cases, typically for lesions mea-
suring less than 30 mm with no mural nodules, and asymptomatic
elderly patients with multiple comorbidities.5,8 Such patients can
be followed with regular imaging, including ultrasound5,8,12–14 and
appearance of symptoms or signs of malignant changes mandate a
surgical intervention.5 In the case of our patient, the presenting
symptoms as well as the size and intraoperative appearance of
the lesion were suggestive of malignancy and prompted a surgical
resection upon diagnosis.
Depending  on the segment of the pancreas involved, a partial
or total pancreatectomy should be performed. Total pancreatec-
tomy is reserved for healthy patients with diffuse multi-centric
disease,15,16 as in our patient. Current treatment recommenda-
tions suggest assessment of resection margins with intra-operative
frozen section in order to ensure that the totality of the dysplastic
lesion has been removed.4,5,17,18 This standard is debated as mul-
tiple studies have shown poor correlation between margin status
and recurrence in the remnant pancreas in cases of non-invasive
IPMN.4,5,17–24
Though there are no prospective comparative data, current
recommendations for surveillance following resection of benign
IPMN are for yearly CT or MRI, with decreased spacing over sev-
eral years.5,25 Authors suggest that the imaging strategy after
resection should be based on the presence or absence of invasive
disease because of implications for recurrence rate: 90% recurrence
within 3 years of surgery for an invasive lesion versus 0–8% in the
non-invasive setting.7,11 Total pancreatectomy however, seems to
effectively prevent recurrence of non-invasive IPMN disease.16–24
Stauffer et al.15 followed 47 patients after total pancreatectomy
for different non-malignant pancreatic pathologies. Twenty one
total pancreatectomies were performed for non-invasive IPMN: 11
simple adenomas, 1 low-moderate dysplasia, and 10 high-grade
dysplasias. No recurrence was  found after a mean follow-up period
of 23 months. Chari et al.18 and Passot et al.11 conﬁrmed the absence
of recurrence after total pancreatectomy for non-invasive disease.
Both authors concluded that regular surveillance imaging during
follow-up was not necessary in this particular setting and should
only be performed if symptoms were to appear. Such a policy in the
present case would have failed to identify IPMN recurrence and
growth. Given the unusual context of this case, the use of FDG-
PET was aimed at ruling out the possibility of multiple sites of
recurrence. This modality was more accurate than CT or MRI  in
distinguishing benign from malignant lesions in 64 patients with
suspected IPMNs studied prospectively.26
4. Conclusion
This report conﬁrms the lacks of prediction of the classiﬁcation
of low-risk IPMN lesion. It reminds us how little is known about the
exact pattern by which extra-pancreatic spread occurs and how
poorly we understand the malignant potential of IPMN. Deﬁni-
tive predictors of recurrence of non-invasive disease have yet to
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e identiﬁed. A vigilant long-term approach to follow-up may  thus
e required even in low risk cases.
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